Cargando…
Alopecia Areata in Latin America: Where are We and Where are We Going?
Alopecia areata (AA) represents an underrecognized burden in Latin America (LA), severely impacting quality of life (QoL). This impact is exacerbated by limited access to specialized dermatologic care and therapies for AA within and among nations. Many of the unmet needs for AA globally also exist i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758465/ https://www.ncbi.nlm.nih.gov/pubmed/36527577 http://dx.doi.org/10.1007/s13555-022-00845-4 |
_version_ | 1784852045246758912 |
---|---|
author | Velásquez-Lopera, Margarita M. Hernández, Natalia Jansen, Angela Marie García, Angela Londoño Luna, Paula Carolina Rico-Restrepo, Mariana del Mar Saez-de-Ocariz, María Tamayo-Buendía, María Margarita Rivitti-Machado, Maria Cecilia |
author_facet | Velásquez-Lopera, Margarita M. Hernández, Natalia Jansen, Angela Marie García, Angela Londoño Luna, Paula Carolina Rico-Restrepo, Mariana del Mar Saez-de-Ocariz, María Tamayo-Buendía, María Margarita Rivitti-Machado, Maria Cecilia |
author_sort | Velásquez-Lopera, Margarita M. |
collection | PubMed |
description | Alopecia areata (AA) represents an underrecognized burden in Latin America (LA), severely impacting quality of life (QoL). This impact is exacerbated by limited access to specialized dermatologic care and therapies for AA within and among nations. Many of the unmet needs for AA globally also exist in LA. The region has geographic, ethnic, cultural, and economic conditions. With new AA medicines targeting immunologic pathways on the horizon, LA must prepare regarding regulatory issues, reimbursement, awareness, and education to give adequate and timely treatment for patients with AA. To address these issues, the Americas Health Foundation convened a panel of six dermatologists from Argentina, Brazil, Colombia, and Mexico who are experts in AA and its comorbidities for a 3-day virtual meeting to discuss AA diagnosis and treatment in LA and create a manuscript offering recommendations to address discussed barriers. This publication examines unmet AA needs in LA, treatment, and innovative therapies and recommends improving AA care. Access constraints to conventional and novel medicines hinder appropriate treatments for patients. Therapy initiation delays can affect QoL, mental health, and disease progression. People with AA face stigmas, discrimination, and misconceptions owing to a lack of disease awareness. With promising new treatments for AA on the horizon, all stakeholders must coordinate efforts to enhance LA’s AA management landscape and improve patient outcomes. |
format | Online Article Text |
id | pubmed-9758465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-97584652022-12-19 Alopecia Areata in Latin America: Where are We and Where are We Going? Velásquez-Lopera, Margarita M. Hernández, Natalia Jansen, Angela Marie García, Angela Londoño Luna, Paula Carolina Rico-Restrepo, Mariana del Mar Saez-de-Ocariz, María Tamayo-Buendía, María Margarita Rivitti-Machado, Maria Cecilia Dermatol Ther (Heidelb) Review Alopecia areata (AA) represents an underrecognized burden in Latin America (LA), severely impacting quality of life (QoL). This impact is exacerbated by limited access to specialized dermatologic care and therapies for AA within and among nations. Many of the unmet needs for AA globally also exist in LA. The region has geographic, ethnic, cultural, and economic conditions. With new AA medicines targeting immunologic pathways on the horizon, LA must prepare regarding regulatory issues, reimbursement, awareness, and education to give adequate and timely treatment for patients with AA. To address these issues, the Americas Health Foundation convened a panel of six dermatologists from Argentina, Brazil, Colombia, and Mexico who are experts in AA and its comorbidities for a 3-day virtual meeting to discuss AA diagnosis and treatment in LA and create a manuscript offering recommendations to address discussed barriers. This publication examines unmet AA needs in LA, treatment, and innovative therapies and recommends improving AA care. Access constraints to conventional and novel medicines hinder appropriate treatments for patients. Therapy initiation delays can affect QoL, mental health, and disease progression. People with AA face stigmas, discrimination, and misconceptions owing to a lack of disease awareness. With promising new treatments for AA on the horizon, all stakeholders must coordinate efforts to enhance LA’s AA management landscape and improve patient outcomes. Springer Healthcare 2022-12-17 /pmc/articles/PMC9758465/ /pubmed/36527577 http://dx.doi.org/10.1007/s13555-022-00845-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Velásquez-Lopera, Margarita M. Hernández, Natalia Jansen, Angela Marie García, Angela Londoño Luna, Paula Carolina Rico-Restrepo, Mariana del Mar Saez-de-Ocariz, María Tamayo-Buendía, María Margarita Rivitti-Machado, Maria Cecilia Alopecia Areata in Latin America: Where are We and Where are We Going? |
title | Alopecia Areata in Latin America: Where are We and Where are We Going? |
title_full | Alopecia Areata in Latin America: Where are We and Where are We Going? |
title_fullStr | Alopecia Areata in Latin America: Where are We and Where are We Going? |
title_full_unstemmed | Alopecia Areata in Latin America: Where are We and Where are We Going? |
title_short | Alopecia Areata in Latin America: Where are We and Where are We Going? |
title_sort | alopecia areata in latin america: where are we and where are we going? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758465/ https://www.ncbi.nlm.nih.gov/pubmed/36527577 http://dx.doi.org/10.1007/s13555-022-00845-4 |
work_keys_str_mv | AT velasquezloperamargaritam alopeciaareatainlatinamericawhereareweandwherearewegoing AT hernandeznatalia alopeciaareatainlatinamericawhereareweandwherearewegoing AT jansenangelamarie alopeciaareatainlatinamericawhereareweandwherearewegoing AT garciaangelalondono alopeciaareatainlatinamericawhereareweandwherearewegoing AT lunapaulacarolina alopeciaareatainlatinamericawhereareweandwherearewegoing AT ricorestrepomariana alopeciaareatainlatinamericawhereareweandwherearewegoing AT delmarsaezdeocarizmaria alopeciaareatainlatinamericawhereareweandwherearewegoing AT tamayobuendiamariamargarita alopeciaareatainlatinamericawhereareweandwherearewegoing AT rivittimachadomariacecilia alopeciaareatainlatinamericawhereareweandwherearewegoing |